on August 26, 2002
Published online before print August 26, 2002, doi: 10.1161/01.HYP.0000032853.95690.26
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 3, 2002
From Service de Cardiologie, Lariboisière Hospital (P.H.), Paris; and Centre d'Investigations Préventives et Cliniques (F.T., A.B., L.G.), Paris, France. * To whom correspondence should be addressed. E-mail: patrick.henry{at}lrb.ap-hop-paris.fr.
Abstract—Impaired fasting glucose (fasting plasma glucose 6.1 to 6.9 mmol/L [110 to 125 mg/dL]) is a common glycemic disorder which usually progress to diabetes mellitus. The relationships between impaired fasting glucose, other risk factors including blood pressure, and mortality have never been clearly investigated. We studied 63 443 consecutive men (ages 21 to 60 years), each of whom had a routine health examination with a fasting plasma glucose measurement. Men with known ischemic cardiac disease and treatment for diabetes or hypertension were excluded. Impaired fasting glucose was found in 10 773 (17.0%) of these men. Mean body mass index, serum triglyceride and cholesterol levels, and systolic, diastolic, and pulse blood pressure were significantly higher for men with impaired fasting glucose compared with those men with normal fasting glucose (fasting plasma glucose 3.9 to 6.0 mmol/L). When adjusted for confounding variables, relative risk of 8-year cardiovascular mortality associated with impaired fasting glucose was dependent on systolic blood pressure level (1.02 [95% CI: 0.62 to 1.70] when <140 mm Hg and 2.10 [95% CI: 1.16 to 3.80] between 140 and 160 mm Hg). Inversely, relative risk of 8-year cardiovascular mortality associated with moderate systolic hypertension (140 to 159 mm Hg) compared with normal systolic blood pressure (<140 mm Hg) was highly dependent on the glycemic status (2.97 [95% CI: 1.58 to 5.55] for men with impaired fasting glucose compared with 1.35 [95% CI: 0.84 to 2.18] in those with normal fasting glucose). Similar results were found concerning overall mortality. In conclusion, the presence of moderate systolic hypertension can identify subjects with impaired fasting glucose who are at risk of cardiovascular and overall mortality, and vice versa, probably through the metabolic syndrome.
Revised on May 28, 2002
Impaired Fasting Glucose, Blood Pressure and Cardiovascular Disease Mortality
Patrick Henry*;
Key words: diabetes mellitus • glucose • blood pressure • cardiovascular disease • mortality • metabolism
This article has been cited by other articles:
 |
|
 |
|
  L. Borbouse, G. M. Dick, S. Asano, S. B. Bender, U. D. Dincer, G. A. Payne, Z. P. Neeb, I. N. Bratz, M. Sturek, and J. D. Tune Impaired function of coronary BKCa channels in metabolic syndrome Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1629 - H1637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Rerkpattanapipat, R. B. D'Agostino Jr, K. M. Link, E. Shahar, J. A. Lima, D. A. Bluemke, S. Sinha, D. M. Herrington, and W. G. Hundley Location of Arterial Stiffening Differs in Those With Impaired Fasting Glucose Versus Diabetes: Implications for Left Ventricular Hypertrophy From the Multi-Ethnic Study of Atherosclerosis Diabetes, April 1, 2009; 58(4): 946 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Guize, F. Thomas, B. Pannier, K. Bean, B. Jego, and A. Benetos All-Cause Mortality Associated With Specific Combinations of the Metabolic Syndrome According to Recent Definitions Diabetes Care, September 1, 2007; 30(9): 2381 - 2387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Sorkin, D. C. Muller, J. L. Fleg, and R. Andres The Relation of Fasting and 2-h Postchallenge Plasma Glucose Concentrations to Mortality: Data from the Baltimore Longitudinal Study of Aging with a critical review of the literature Diabetes Care, November 1, 2005; 28(11): 2626 - 2632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Wen, T. Y. D. Cheng, S. P. Tsai, H. L. Hsu, and S. L. Wang Increased Mortality Risks of Pre-Diabetes (Impaired Fasting Glucose) in Taiwan Diabetes Care, November 1, 2005; 28(11): 2756 - 2761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Thomas, K. Bean, B. Pannier, J.-M. Oppert, L. Guize, and A. Benetos Cardiovascular Mortality in Overweight Subjects: The Key Role of Associated Risk Factors Hypertension, October 1, 2005; 46(4): 654 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Zhang, J. D. Knudson, S. Setty, A. Araiza, U. D. Dincer, L. Kuo, and J. D. Tune Coronary arteriolar vasoconstriction to angiotensin II is augmented in prediabetic metabolic syndrome via activation of AT1 receptors Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2154 - H2162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kario, J. Ishikawa, S. Hoshide, Y. Matsui, M. Morinari, K. Eguchi, S. Ishikawa, and K. Shimada Diabetic Brain Damage in Hypertension: Role of Renin-Angiotensin System Hypertension, May 1, 2005; 45(5): 887 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Rodriguez-Manas, M. Castro, and J. Manzarbeitia Review: Cardiovascular risk and diabetes in old people The British Journal of Diabetes & Vascular Disease, January 1, 2005; 5(1): 7 - 11. [Abstract] [PDF]
|
|
|
|
 |
|
 E. B. Levitan, Y. Song, E. S. Ford, and S. Liu Is Nondiabetic Hyperglycemia a Risk Factor for Cardiovascular Disease?: A Meta-analysis of Prospective Studies Arch Intern Med, October 25, 2004; 164(19): 2147 - 2155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Verdecchia, G. Reboldi, F. Angeli, C. Borgioni, R. Gattobigio, L. Filippucci, S. Norgiolini, C. Bracco, and C. Porcellati Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects Hypertension, May 1, 2004; 43(5): 963 - 969. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. Cohen, S. M. Hailpern, and M. H. Alderman Glucose-Cholesterol Interaction Magnifies Coronary Heart Disease Risk for Hypertensive Patients Hypertension, May 1, 2004; 43(5): 983 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Prisant Diabetes Mellitus: An Imperative for Prevention and Intense Management J. Clin. Pharmacol., April 1, 2004; 44(4): 394 - 396. [Full Text] [PDF]
|
|
|
|
|
|
L. M. Prisant Preventing Type II Diabetes Mellitus J. Clin. Pharmacol., April 1, 2004; 44(4): 406 - 413. [Abstract] [Full Text] [PDF]
|
|